TherapeuticsMD
TXMD
117 hedge funds and large institutions have $821M invested in TherapeuticsMD in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 54 increasing their positions, 33 reducing their positions, and 30 closing their positions.
167% more call options, than puts
Call options by funds: $4.48M | Put options by funds: $1.68M
64% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 33
0.13% less ownership
Funds ownership: 1.66% → 1.53% (-0.13%)
15% less funds holding
Funds holding: 138 → 117 (-21)
30% less capital invested
Capital invested by funds: $1.18B → $821M (-$359M)
67% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 30
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$12.9M |
| 2 |
JP Morgan Chase
New York
|
+$9.83M |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
+$8.13M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$3.72M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$27.8M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$24.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$13M |
| 5 |
Millennium Management
New York
|
-$6.06M |
TXMD Hedge Fund Activity: Q2 2017 in Review
117 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q2 2017, worth a combined $821M — down 30% from $1.18B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of TXMD and 10 opened new positions — a net loss of 20 holders — while 33 trimmed existing stakes and 54 added.
The largest buyer was Bank of New York Mellon, adding an estimated $12.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $27.8M.
- 117 institutional investors held TherapeuticsMD (TXMD) as of Q2 2017, down from 138 in Q1 2017.
- Funds reported $821M of TherapeuticsMD stock for Q2 2017, down 30% quarter-over-quarter.
- 10 funds opened new TherapeuticsMD positions in Q2 2017 and 30 closed out, a net change of -20 holders.
- The largest TherapeuticsMD buyer in Q2 2017 was Bank of New York Mellon, an estimated $12.9M added.
- The largest TherapeuticsMD seller in Q2 2017 was T. Rowe Price Associates, an estimated $27.8M sold.
Based on aggregated 13F filings for Q2 2017.